Replies to post #375160 on Innovation Pharmaceuticals Inc (IPIX)

[MinnieM]

We've been updated on other trials this year. The Ulcerative Colitis (UC) trial is likely up next.

The update also included mention of an upcoming Oral Mucositis (OM) trial in 2022.

https://www.ipharminc.com/press-release/2021/5/13/innovation-pharma-files-form-10-q-patient-enrollment-in-phase-2-clinical-trial-of-brilacidin-for-covid-19-tops-70-percent
Posted May 13, 2021

Development work related to the formulation and manufacture of Brilacidin in capsule form is underway to support our Phase 2 trial in Ulcerative Colitis planned to commence this year. Additional work tied to starting, in 2022, a planned Phase 3 study of Brilacidin in Oral Mucositis is also in progress. We aim to maintain momentum across our clinical programs.”

None of us know whether or not the current Brilacidin ph2 covid trial will be successful. So much also depends on side effects of SOC which in some cases might produce side effects that are attributed to Covid. (I've only recently discovered this might be a possibility). I'm glad our covid trial is being held in many different locations.

It's good that UC and OM are being lined up in case covid trial doesn't make endpoints. Hoping we have enough funds for at least the UC trial to move forward.